IVOG
Vanguard S&P Mid-Cap 400 Growth ETF
SMB
UMD
Adj. R2
0.915
Rel. Sharpe
0.953
Mkt beta
1.01
AUM
US$1.5B
MER
0.10%
Valuation
122
ETF comparison
Verified factor-similar pair
IVOG vs USVM
These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.
SMB
UMD
Similarity score
86
Verified similar
The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.
Quick Read
- USVM has the higher backtested relative Sharpe (1.046 vs 0.953).
- IVOG has the lower published fee (0.10% vs 0.29%).
- USVM is cheaper on dividend valuation (79 vs 122, where 100 is each fund's historical median).
- USVM has the stronger regression fit (adjusted R-squared 0.962 vs 0.915).
These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.
USVM
VictoryShares US Small Mid Cap Value Momentum ETF
SMB
UMD
Adj. R2
0.962
Rel. Sharpe
1.046
Mkt beta
0.97
AUM
US$1.5B
MER
0.29%
Valuation
79
Factor Exposure Match
Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.
SMB
diff -0.33
HML
diff -0.17
RMW
diff -0.02
CMA
diff -0.06
UMD
diff +0.01
Why This Pair Matches
Exposure level
83
Exposure shape
98
Mkt beta diff
0.04
Rel. Sharpe diff
0.094
This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.
Monthly updates
Get the next US ETF leaders update
Get one monthly email when the US leaders table refreshes, plus methodology and comparison-page updates.
Monthly leaders refresh
Download-access updates
Low-volume research notes
One monthly email when the data drop lands. This browser will remember you after signup.